Pitsios Constantinos, Papadopoulos Dimitrios, Kompoti Evangelia, Manoussakis Emmanouel, Garris Viktor, Petalas Konstantinos, Tassios Ioannis, Baibas Nikolaos, Kontou-Fili Kalliopi, Saxoni-Papageorgiou Photini, Papadopoulos Nikolaos G
Department of Allergology and Clinical Immunology, Laikon General Hospital, Athens, Greece.
Ann Allergy Asthma Immunol. 2006 May;96(5):673-8. doi: 10.1016/S1081-1206(10)61064-2.
The preventive use of medications has been proposed to be effective in the treatment of seasonal rhinitis.
To evaluate the efficacy and safety of mometasone furoate and nedocromil sodium nasal sprays as prophylactic treatment for moderate to severe seasonal allergic rhinitis (SAR).
Sixty-one patients were recruited from 3 referral allergy centers. Inclusion criteria were history of SAR for 2 years or longer, sensitization to relevant local pollen (grasses, Parietaria, and olive), and age older than 12 years.
An open-label, randomized, parallel-group, "real-life" study design was used. Patients received mometasone furoate nasal spray once daily or nedocromil sodium nasal spray 3 times daily starting 2 to 4 weeks before the pollen season and continuing for up to 4 months. Instructions regarding the use of additional medications were given. Diary cards recording symptoms, use of medication, and adverse events were kept by the patients.
All 61 patients completed the study. The prophylactic use of mometasone furoate vs nedocromil sodium led to significantly more days without symptoms (75.1% vs 54.5%; P < .001). The mometasone furoate group also had lower nasal symptom scores (mean, 1.4 vs 2.9; median, 0 vs 2; P < .001) and was more satisfied (93.1% vs 43.5%; P < .001). No serious adverse event was recorded, and there was no difference between the treatments in any adverse event.
Prophylactic administration of mometasone furoate before the pollen season is safe and may lead to improved control of SAR compared with the use of nedocromil sodium.
已提出预防性使用药物对季节性鼻炎的治疗有效。
评估糠酸莫米松和色甘酸钠鼻喷雾剂作为中重度季节性过敏性鼻炎（SAR）预防性治疗的疗效和安全性。
从3个转诊过敏中心招募了61名患者。纳入标准为有2年或更长时间的SAR病史、对相关本地花粉（草、墙草属植物和橄榄）过敏，以及年龄大于12岁。
采用开放标签、随机、平行组、“真实生活”研究设计。患者在花粉季节开始前2至4周开始，每天一次使用糠酸莫米松鼻喷雾剂或每天三次使用色甘酸钠鼻喷雾剂，并持续使用长达4个月。给出了关于使用其他药物的说明。患者保留记录症状、药物使用和不良事件的日记卡。
所有61名患者均完成了研究。预防性使用糠酸莫米松与色甘酸钠相比，无症状天数显著更多（75.1%对54.5%；P <.001）。糠酸莫米松组的鼻部症状评分也更低（平均值，1.4对2.9；中位数，0对2；P <.001），且满意度更高（93.1%对43.5%；P <.001）。未记录到严重不良事件，且在任何不良事件方面，两种治疗方法之间无差异。
在花粉季节前预防性给予糠酸莫米松是安全的，与使用色甘酸钠相比，可能会改善对SAR的控制。
